X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (204) 204
humans (192) 192
index medicus (187) 187
transplantation (184) 184
middle aged (156) 156
female (151) 151
male (148) 148
adult (147) 147
aged (121) 121
stem cells (112) 112
hematology, oncology and palliative medicine (103) 103
article (87) 87
immunology (87) 87
treatment outcome (76) 76
hematopoietic stem cells (74) 74
hematopoietic stem cell transplantation (67) 67
retrospective studies (67) 67
adolescent (55) 55
cancer (53) 53
chemotherapy (52) 52
oncology (52) 52
young adult (52) 52
transplantation, homologous (51) 51
bone-marrow-transplantation (49) 49
hematopoietic stem cell transplantation - methods (49) 49
prognosis (48) 48
care and treatment (45) 45
transplantation conditioning - methods (44) 44
disease-free survival (43) 43
survival analysis (43) 43
analysis (40) 40
leukemia (40) 40
multiple myeloma (38) 38
stem cell transplantation (38) 38
survival (38) 38
survival rate (37) 37
stem-cell transplantation (36) 36
transplantation, autologous (36) 36
recurrence (35) 35
hemic and lymphatic diseases (32) 32
acute myeloid-leukemia (31) 31
risk factors (31) 31
therapy (31) 31
versus-host-disease (31) 31
patient outcomes (30) 30
melphalan (29) 29
hematopoietic stem cell transplantation - adverse effects (28) 28
relapse (28) 28
transplantation conditioning (27) 27
abridged index medicus (26) 26
busulfan (26) 26
follow-up studies (26) 26
lymphomas (26) 26
multiple myeloma - therapy (26) 26
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
mortality (24) 24
blood (23) 23
child (23) 23
remission induction (23) 23
risk (23) 23
graft vs host disease - etiology (22) 22
leukemia, myeloid, acute - therapy (22) 22
surgical procedures, operative (22) 22
cyclophosphamide (21) 21
fludarabine (21) 21
allografts (20) 20
hematologic neoplasms - therapy (20) 20
multiple myeloma - mortality (20) 20
vidarabine - analogs & derivatives (20) 20
health aspects (19) 19
minimal residual disease (19) 19
cytogenetics (18) 18
disease (18) 18
graft vs host disease - prevention & control (18) 18
myelodysplastic syndrome (18) 18
outcomes (18) 18
allogeneic transplantation (17) 17
aml (17) 17
myelodysplastic syndromes - therapy (16) 16
bone-marrow (15) 15
bortezomib (15) 15
diseases (15) 15
hematopoietic stem cell transplantation - mortality (15) 15
melphalan - administration & dosage (15) 15
prognostic-factors (15) 15
time factors (15) 15
trial (15) 15
usage (15) 15
aged, 80 and over (14) 14
combined modality therapy (14) 14
impact (14) 14
t cells (14) 14
vidarabine - administration & dosage (14) 14
acute myelogenous leukemia (13) 13
acute myeloid leukemia (13) 13
adults (13) 13
bone marrow (13) 13
child, preschool (13) 13
dosage and administration (13) 13
graft vs host disease - mortality (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Emerging cancer therapeutics, ISBN 1933864680, Volume 2, issue 2.
Book
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3363 - 3376
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 24, pp. 2305 - 2315
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 831 - 835
Table SII. The JAK2 V617F AS-qPCR cutoff of >0.05% at day +180 following allogeneic hematopoietic stem cell transplantation reliably distinguished JAK2 V617F... 
myelofibrosis | minimal residual disease | allogeneic hematopoietic stem cell transplantation | MUTATION | MYELOPROLIFERATIVE NEOPLASMS | ASSAYS | HEMATOLOGY | Transplantation | Hematopoietic stem cells | Stem cells | Janus kinase 2 | Myelofibrosis
Journal Article
Cancer, ISSN 0008-543X, 09/2016, Volume 122, Issue 17, pp. 2680 - 2688
BACKGROUND More active high‐dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with... 
high‐dose chemotherapy | vorinostat | autologous stem‐cell transplantation | azacitidine | lymphoma | phase 1 trial | Autologous stem-cell transplantation | Azacitidine | Lymphoma | High-dose chemotherapy | Vorinostat | Phase 1 trial | autologous stem-cell transplantation | high-dose chemotherapy | PROGNOSTIC-FACTORS | RANDOMIZED-TRIAL | CLASSIFICATION | GEMCITABINE | BUSULFAN | PARMA TRIAL | HODGKINS-DISEASE | ONCOLOGY | AGGRESSIVE LYMPHOMA | STEM-CELL TRANSPLANTATION | MYELODYSPLASTIC SYNDROMES | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Busulfan - administration & dosage | Neoplasm Recurrence, Local - pathology | Young Adult | Lymphoma - drug therapy | Hydroxamic Acids - administration & dosage | Adult | Female | Lymphoma - pathology | Child | Azacitidine - administration & dosage | Lymphoma - classification | Deoxycytidine - administration & dosage | Lymphoma - genetics | Survival Rate | Neoplasm Recurrence, Local - classification | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Epigenesis, Genetic - genetics | Adolescent | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Drug Resistance, Neoplasm - drug effects | Complications and side effects | Chemotherapy | Usage | Care and treatment | Dosage and administration | Lymphomas | Risk factors | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 2018, Volume 54, Issue 4, pp. 601 - 606
6 Allogeneic SCT for older patients remains challenging at least in part due to graft-versus-host disease (GVHD) and higher non-relapse mortality (NRM). We... 
ACUTE MYELOGENOUS LEUKEMIA | PREVENTION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | FLUDARABINE | TRANSPLANTATION | TRIAL | SINGLE-AGENT | ONCOLOGY | OUTCOMES | BEHALF | HEMATOLOGY | ELDERLY-PATIENTS | Prospective Studies | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Cyclophosphamide - therapeutic use | Tacrolimus - therapeutic use | Pilot Projects | Mycophenolic Acid - therapeutic use | Graft vs Host Disease - drug therapy | Cyclophosphamide - pharmacology | Mycophenolic Acid - pharmacology | Tacrolimus - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Female | Unrelated Donors | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Leukemia, Myeloid, Acute - therapy | Cyclophosphamide | Usage | Tacrolimus | Aged patients | Graft versus host reaction | Dosage and administration | Transplantation | Drug therapy | Health aspects | Hematopoietic stem cells | Graft-versus-host reaction | Mycophenolic acid | Stability | Hematology | Transplants & implants | Prophylaxis | Stem cell transplantation | Patients | Hemopoiesis | Stem cells | Melphalan | Histocompatibility antigen HLA | Mycophenolate mofetil | Conditioning | Mud | hematological malignancies | matched unrelated donor transplant | graft-vs-host prevention | post-transplant cyclophosphamide | survival
Journal Article
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 14, pp. 2661 - 2670
BACKGROUND Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only treatment with a curative potential for myelodysplastic syndrome (MDS)... 
stem cell transplant | MDS | elderly | cytogenetics and comorbidity | PROGNOSTIC SCORING SYSTEM | GERIATRIC ASSESSMENT | DONOR | BONE-MARROW-TRANSPLANTATION | MONOSOMAL KARYOTYPE | SYNDROMES MDS | ACUTE MYELOID-LEUKEMIA | VERSUS-HOST-DISEASE | ONCOLOGY | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | ELDERLY-PATIENTS | Graft vs Host Disease - epidemiology | Prognosis | Anemia, Refractory, with Excess of Blasts - therapy | Anemia, Refractory, with Excess of Blasts - genetics | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Myelodysplastic Syndromes - classification | Male | Cause of Death | Myelodysplastic Syndromes - therapy | Anemia, Refractory, with Excess of Blasts - epidemiology | Female | Retrospective Studies | Transplantation Conditioning - methods | Comorbidity | Risk Factors | Proportional Hazards Models | Survival Rate | Treatment Outcome | Myelodysplastic Syndromes - epidemiology | Monosomy - genetics | Disease Progression | Chromosome Aberrations | Leukemia, Myelomonocytic, Chronic - therapy | Aged | Myelodysplastic Syndromes - genetics | Hematopoietic Stem Cell Transplantation - methods | Leukemia, Myelomonocytic, Chronic - epidemiology | Transplantation, Homologous - methods | Care and treatment | Usage | Stem cells | Transplantation | Health aspects | Myelodysplastic syndromes | Refractory anemia | Transplants & implants | Stem cell transplantation | Myelodysplastic syndrome | Risk factors | Incidence | Confidence intervals | Risk assessment | Older people | Conditioning | Blast cells | Cell survival | Risk groups | Abnormalities | Health risks | Fourier analysis | Patients | Survival | Hemopoiesis | Cytogenetics | Cancer | Geriatrics
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2018, Volume 24, Issue 3, pp. S322 - S323
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.